- Yellow fever vaccines, offering effective immunization against the yellow fever virus, are increasingly vital components of public health initiatives and international travel regulations in both endemic and non-endemic regions due to their proven efficacy, long-lasting protection, and critical role in outbreak prevention and control.
- The escalating demand for yellow fever vaccines is primarily fueled by the rising incidence of vector-borne diseases, increasing international travel to high-risk regions, and growing governmental and non-governmental efforts to expand immunization coverage in vulnerable populations.
- Africa dominates the yellow fever market with the largest revenue share of 47.6% in 2025, characterized by a high disease burden, strong presence of immunization campaigns, and support from global health organizations, with countries like Nigeria and the Democratic Republic of Congo experiencing substantial growth in vaccination rates, particularly through mass immunization drives and integrated disease surveillance programs.
- Latin America is expected to be the fastest growing region in the yellow fever market during the forecast period due to recent outbreaks, increased vaccination mandates for travellers, and enhanced public health infrastructure.
- Live attenuated vaccine segment is expected to dominate the yellow fever market with a market share of 69.4% in 2025, driven by its long-established use, high efficacy, and endorsement by the World Health Organization (WHO) as the primary preventive measure for yellow fever
